Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002666380 | SCV003719795 | uncertain significance | Inborn genetic diseases | 2022-07-27 | criteria provided, single submitter | clinical testing | The c.2057G>A (p.R686Q) alteration is located in exon 16 (coding exon 16) of the BBS2 gene. This alteration results from a G to A substitution at nucleotide position 2057, causing the arginine (R) at amino acid position 686 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005021756 | SCV005643988 | uncertain significance | Bardet-Biedl syndrome 2; Retinitis pigmentosa 74 | 2024-06-14 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004733608 | SCV005344757 | uncertain significance | BBS2-related disorder | 2024-07-01 | no assertion criteria provided | clinical testing | The BBS2 c.2057G>A variant is predicted to result in the amino acid substitution p.Arg686Gln. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0050% of alleles in individuals of East Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |